Literature DB >> 19035684

Pathological satiety caused by brainstem hemangioblastoma.

Debbie K Song1, Russell R Lonser.   

Abstract

Because of the multiplicity and saltatory growth pattern associated with central nervous system hemangioblastomas in von Hippel-Lindau (VHL) disease, resection of individual tumors is usually reserved until symptoms occur, to avoid unnecessary surgery over the lifetime of a patient. Brainstem hemangioblastomas in VHL typically cause lower cranial nerve dysfunction, long-tract signs, sensory impairment, and gait abnormalities. The authors report on a 16-year-old girl with VHL who presented with abnormal early satiety resulting in growth and developmental arrest associated with a growing obex hemangioblastoma. Tumor resection resulted in restoration of appetite, with rapid weight gain, growth in stature, and onset of menses. These findings indicate that caudal brainstem-mediated mechanisms have a profound effect on satiety. Moreover, brainstem hemangioblastomas may present with abnormalities in satiety and feeding that can be effectively reversed with resection.

Entities:  

Mesh:

Year:  2008        PMID: 19035684      PMCID: PMC2770704          DOI: 10.3171/PED.2008.2.12.397

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  17 in total

Review 1.  Central nervous system control of food intake.

Authors:  M W Schwartz; S C Woods; D Porte; R J Seeley; D G Baskin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

2.  Hemangioblastoma of the obex mimicking anorexia nervosa.

Authors:  G Pavesi; S Berlucchi; A Feletti; G Opocher; R Scienza
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

3.  Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease.

Authors:  J E Conway; D Chou; R E Clatterbuck; H Brem; D M Long; D Rigamonti
Journal:  Neurosurgery       Date:  2001-01       Impact factor: 4.654

4.  Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment.

Authors:  Joshua M Ammerman; Russell R Lonser; James Dambrosia; John A Butman; Edward H Oldfield
Journal:  J Neurosurg       Date:  2006-08       Impact factor: 5.115

Review 5.  Gustatory neural processing in the hindbrain.

Authors:  J B Travers; S P Travers; R Norgren
Journal:  Annu Rev Neurosci       Date:  1987       Impact factor: 12.449

Review 6.  Central nervous system control of food intake and body weight.

Authors:  G J Morton; D E Cummings; D G Baskin; G S Barsh; M W Schwartz
Journal:  Nature       Date:  2006-09-21       Impact factor: 49.962

7.  Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease.

Authors:  Robert J Weil; Russell R Lonser; Hetty L DeVroom; John E Wanebo; Edward H Oldfield
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

8.  The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease.

Authors:  John E Wanebo; Russell R Lonser; Gladys M Glenn; Edward H Oldfield
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Cholecystokinin decreases sucrose intake in chronic decerebrate rats.

Authors:  H J Grill; G P Smith
Journal:  Am J Physiol       Date:  1988-06
View more
  2 in total

1.  Long-term outcome after resection of brainstem hemangioblastomas in von Hippel-Lindau disease.

Authors:  Joshua J Wind; Kamran D Bakhtian; Jennifer A Sweet; Gautam U Mehta; Jayesh P Thawani; Ashok R Asthagiri; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2010-10-08       Impact factor: 5.115

2.  Biological stoichiometry in tumor micro-environments.

Authors:  Irina Kareva
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.